Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radius Braced For Second CHMP No For Abaloparatide

Executive Summary

Another expected knockback by the European Medicines Agency's scientific committee is expected for Radius' lead product after the company revealed a negative trend vote for the osteoporosis therapy.

You may also be interested in...



OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.

OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.

Crunch Time For 18 Products Seeking EU Approval, "No" Stays In Place for Radius

Two drugs filed via the rarely-used used EU pediatric-use marketing authorization pathway are among 18 products up for an opinion from the European Medicines Agency this week on whether they should be approved. Also, Radius Health has already said its appeal has failed. What news will there be on Portola's appeal?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132380

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel